Neuroxelin is a seller-defined blend
Neuroxelin is not one chemical entity or approved medicine. Sellers commonly describe a mixture of PE-22-28, Pinealon/EDR, N-acetyl Semax, and N-acetyl Selank, but the name is not a recognized standard and formulations may vary.
The finished blend has no clinical evidence
PE-22-28 evidence is limited to cells and rodents.[1] Semax and Selank have limited, regionally concentrated human literature, while the N-acetyl variants and Pinealon have separate and weaker evidence. No study has tested the four ingredients together, demonstrated synergy, or established effects on depression, anxiety, memory, cognition, stroke recovery, or neuroprotection.
Psychiatric and neurologic safety is unknown
No blend-specific pharmacokinetics, interactions, adverse-event monitoring, pregnancy evidence, seizure assessment, mood-switch risk, or long-term safety database exists. Mixing four central-nervous-system research compounds makes component-specific findings less—not more—predictive.
Regulatory status
Neuroxelin and its stated components are not FDA-approved as this product. FDA's Semax review and substance records do not constitute approval.[2] Compounded drugs are not premarket-verified for safety, effectiveness, or quality.[3] Teloryx publishes no blend recipe or dose.